

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2013

**BIOSCRIP, INC.**

(Exact name of Registrant as specified in its charter)

Delaware

000-28740

05-0489664

(State of Incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification No.)

100 Clearbrook Road, Elmsford, New York

10523

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (914) 460-1600

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 – Other Events.**

On June 17, 2013, BioScrip, Inc. (“BioScrip”) issued a press release announcing that it extended the consent payment deadline, the withdrawal deadline and the expiration date to 5:00 p.m. New York City time on July 8, 2013 with respect to its previously announced cash tender offer and consent solicitation for any and all of its \$225 million aggregate principal amount of 10¼ % Senior Notes due 2015 (the “Notes”). The Company also announced that, as of the close of business on June 14, 2013, the consent of approximately \$107.4 million or 47.72% in aggregate principal amount of the outstanding Notes have been received. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01 – Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release dated June 17, 2013.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSCRIP, INC.**

Date: June 17, 2013

By: /s/ Kimberlee C. Seah  
Kimberlee C. Seah  
Senior Vice President and General Counsel

---

**Index to Exhibits**

**Exhibit Number**

**Description**

99.1

Press Release dated June 17, 2013.

---

**FOR IMMEDIATE RELEASE****BIOSCRIP EXTENDS THE CONSENT PAYMENT DEADLINE AND EXPIRATION DATE FOR ITS PREVIOUSLY ANNOUNCED TENDER OFFER AND CONSENT SOLICITATION**

**Elmsford, NY – June 17, 2013** – BioScrip, Inc. (NASDAQ: BIOS) (“BioScrip”) previously announced that it had commenced a cash tender offer (the “Tender Offer”) and consent solicitation (the “Consent Solicitation,” and together with the Tender Offer, the “Offer”) for any and all of its \$225 million aggregate principal amount of 10¼% Senior Notes due 2015 (CUSIP No. 09069NAC2) (the “Notes”). The Offer is described in the Offer to Purchase and Consent Solicitation Statement dated June 3, 2013 (the “Offer to Purchase”).

In connection with BioScrip’s recently disclosed acquisition of the business of CarePoint Partners Holdings LLC and its subsidiaries (collectively, “CarePoint Partners”), BioScrip announced today that it has agreed with the lenders arranging its previously announced senior credit financing to modify the terms of such financing to provide sufficient additional capacity to consummate both the refinancing of BioScrip’s existing indebtedness and the acquisition of CarePoint Partners. In connection with the modification of the terms of its senior credit financing, BioScrip also announced today that it has extended each of the consent payment deadline for the Consent Solicitation, the withdrawal deadline for the Consent Solicitation and the expiration date of the Offer to 5:00 p.m., New York City time, on July 8, 2013, unless further extended by BioScrip in its sole discretion (the “Expiration Date”). Holders who validly tender their Notes and provide their consents to the proposed amendments to the indenture governing the Notes prior to the Expiration Date will receive \$1,056.25 per \$1,000 principal amount of the Notes (which amount includes a consent payment of \$30.00 per \$1,000 principal amount of the Notes), plus any accrued and unpaid interest on the Notes up to, but not including, the payment date for such Notes.

Except for the extension described above, all other terms and conditions of the Offer remain unchanged. As of the close of business on June 14, 2013, based on information provided by Global Bondholder Services Corporation, the Depositary and Information Agent for the Offer, the consents of approximately \$107.4 million in aggregate principal amount, or 47.72%, of the outstanding Notes have been received.

BioScrip’s obligation to accept for purchase, and to pay for, any Notes in the Offer is subject to satisfaction or waiver of a number of conditions that are set forth in the Offer to Purchase, including, without limitation, (i) the receipt by BioScrip of net proceeds from the new senior secured term loan and revolving credit facility on terms and conditions satisfactory to BioScrip in an amount that is sufficient to pay the total consideration (including consent payment) in respect of all Notes (regardless of the actual amount of Notes tendered) plus estimated fees and expenses relating to the Offer (the “Financing Condition”) and (ii) the receipt of the required consents to amend and supplement the indenture governing the Notes in connection with the Consent Solicitation and the execution of a supplemental indenture effecting such amendments by the applicable parties. There can be no assurance that the Financing Condition and the transactions contemplated by the Financing Condition will be consummated or that any other condition to the Offer will be satisfied. BioScrip reserves the right to waive any of the conditions to the Offer. If the Offer is terminated or withdrawn, no consideration will be paid or become payable in respect of the tendered Notes and the Notes tendered pursuant to the Offer will be promptly returned to the tendering holders.

---

BioScrip has engaged SunTrust Robinson Humphrey, Inc., Jefferies LLC and Morgan Stanley & Co. LLC as the dealer managers for the Offer. Persons with questions regarding the Offer should contact SunTrust Robinson Humphrey at (404) 926-5051, Jefferies LLC at (888) 708-5831 or Morgan Stanley at (800) 624-1808 (toll free) or (212) 761-1057 (collect). Requests for copies of the Offer to Purchase or other Offer materials may be directed to Global Bondholder Services Corporation, the Information Agent, at (866) 736-2200 (toll free) or (212) 430-3774 (collect).

This press release does not constitute an offer to purchase the Notes or a solicitation of Consents to amend the Indenture. The Offer is made solely pursuant to the Offer to Purchase. The Offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

#### **About BioScrip, Inc.**

BioScrip, Inc. provides comprehensive infusion and home care solutions. By partnering with patients, physicians, healthcare payors, government agencies and pharmaceutical manufacturers, we are able to provide access to infusible medications and management solutions. Our goal is to optimize outcomes for chronic and other complex healthcare conditions and enhance the quality of patient life. BioScrip brings clinical competence in providing high-touch, comprehensive infusion and nursing services to patients in the most convenient ways possible. Through our customer services and treatments we aim to ensure the best possible therapy outcome.

#### **Forward-Looking Statements – Safe Harbor**

*This press release includes statements that may constitute "forward-looking statements" conveying management's expectations as to the future based on current plans, estimates and projections. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, forward-looking statements can be identified by words such as "may," "should," "could," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "predict," "potential," "continue" or comparable terms. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and, because such statements inherently involve risks and uncertainties, actual results may differ materially from those in the forward-looking statements. The forward-looking statements contained in this press release include statements related to the Offer, including the Expiration Date and possible completion of the Offer, and the expected entry into a new senior secured term loan and new revolving credit facility. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. BioScrip does not undertake any duty to update these forward-looking statements after the date hereof, even though BioScrip's situation may change in the future, except, with respect to the Offer, as required by law. All of the forward-looking statements herein are qualified by these cautionary statements.*

#### **Contacts:**

Hai Tran  
BioScrip, Inc.  
952-979-3768

Lisa Wilson  
In-Site Communications, Inc.  
212-759-3929

---